Multiple Sclerosis, Relapsing-Remitting
"Multiple Sclerosis, Relapsing-Remitting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Descriptor ID |
D020529
|
| MeSH Number(s) |
C10.114.375.500.600 C10.314.350.500.600 C20.111.258.250.500.600
|
| Concept/Terms |
Multiple Sclerosis, Relapsing-Remitting- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Relapsing Remitting
- Remitting-Relapsing Multiple Sclerosis
- Multiple Sclerosis, Remitting-Relapsing
- Remitting Relapsing Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis, Relapsing-Remitting".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis, Relapsing-Remitting".
This graph shows the total number of publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in this website by year, and whether "Multiple Sclerosis, Relapsing-Remitting" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2009 | 4 | 0 | 4 |
| 2010 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Profiles.
-
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct; 13(5):261-268.
-
Association Between Frailty and Free-Living Walking Performance in People With Multiple Sclerosis. Phys Ther. 2023 05 04; 103(5).
-
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730.
-
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. CNS Drugs. 2022 09; 36(9):977-993.
-
Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells. Int J Mol Sci. 2021 Sep 10; 22(18).
-
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 07; 38(7):3724-3742.
-
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct; 267(10):2851-2864.
-
Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. J Neurol. 2020 01; 267(1):125-131.
-
Deterioration of specific aspects of gait during the instrumented 6-min walk test among people with multiple sclerosis. J Neurol. 2019 Dec; 266(12):3022-3030.
-
Outcomes of natalizumab treatment within 3?years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019 Jun 08; 19(1):116.